In 1992, Shijiazhuang Yiling Pharmaceutical Co.Ltd.was initially founded by Professor Wu Yiling,a prominent member of China Academy of Engineering, and the company was successfully listed in Shenzhen Stock Exchange in 2011. With more than 16,000 employees, Yiling Group has multiple subsidiaries around the world. Yiling Group continues to grow steadily and robustly, with annual revenue exceeding USD 1.25 Billion in 2021, Yiling has developed into a great integrated pharmaceutical company which worth over USD 6.25 Billion.
As a wholly-owned subsidiary of Yiling Group, Yiling Pharmaceutical Ltd. is solely responsible for the innovative development of chemical drugs.
Yiling Pharma is managed by strong team of R&D, Production, Quality, Marketing & Sales. Management team possess multinational pharma corporation background and excellent expertise. Yiling ranks in one of the largest China’s enterprises exporting finished drugs to regulated market. Facilities have been certified by US FDA, MHRA,China NMPA, TGA, Health Canada and Medsafe for many times.